Loading...
Market
Will Takeda report increased Vyvanse sales in Q4 2024 compared to Q4 2023?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Takeda Pharmaceutical's official financial reports
Story
DEA Increases Vyvanse Production Limit by 24% to Address ADHD Drug Shortage
Sep 4, 2024, 11:15 AM
The U.S. Drug Enforcement Administration (DEA) has increased the production limit for Takeda Pharmaceutical's ADHD drug Vyvanse and its generic versions by about 24% to address the ongoing shortage of the medication in the United States. This decision aims to mitigate the impact of the current drug shortage affecting ADHD treatment. The US is allowing 24% more production of Vyvanse and its generic rivals to address treatment shortages.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
More than 20% increase • 25%
10%-20% increase • 25%
0%-10% increase • 25%
Decrease • 25%
